department, and the study should be interpreted within an additional 20 min (door to interpretation time of 45 min). 7 3. Importantly, do not delay CT perfusion examination and/or transportation of the patient to the angio suite while awaiting the blood test results . a. Serum creatinine measurement is typically required prior to the procedures using iodinated contrast. However, the 2010 American College of Radiology Manual on Contrast Media recommends checking of creatinine only for patients who have established risk factors for contrast-induced nephropathy. 8 The authors of this handbook proceed with CT perfusion and with angiography in patients with acute ischaemic stroke prior to the blood test results, if necessary, on the grounds that checking of creatinine is really not necessary in many patients, and that the bene fi t of rapid diagnosis and treatment justi fi es the relatively low risk of nephropathy. 9,10 b. Likewise, do not delay transportation of the patient to the angio suite pending platelet count and coagulation studies, if IA thrombolysis is anticipated. The endovascular procedure can be started and the vascular access can be accomplished while awaiting the laboratory results. 4. Implement effective triage; bump or reschedule elective cases and other clinic activities to accommodate the patient suffering from acute stroke.
Thrombolytic AgentsSeveral thrombolytic agents are available (Table 9.1 ). Most work by converting plasminogen to plasmin. Plasmin then cleaves the fi brin meshwork of the thrombus, leading to lysis. Urokinase and streptokinase are the fi rst-generation agents and are not fi brin-(i.e., clot) speci fi c. Urokinase, a naturally occurring serine protease with low antigenicity, was withdrawn from the market in the United States for several years due to manufacturing issues, but has recently been reintroduced. Streptokinase, an activator of plasminogen but not an enzyme, despite the name, has limited usefulness because many patients have pre-formed anti-streptococcal antibodies and have the potential for an anaphylactic reaction to this agent. Second-generation agents are fi brin-speci fi c and include prourokinase (aka pro-UK, or saruplase) and alteplase. They have the drawback of lowering the levels of fi brinogen and plasminogen, leading to an increased risk of haemorrhagic complications. Prourokinase is a precursor of urokinase and is converted on the surface of the thrombus to urokinase by fi brinbound plasmin, resulting in superior fi brin speci fi city and lytic ef fi cacy, compared to urokinase. Prourokinase has the distinction of being the agent used in the Prolyse in Acute Cerebral Thromboembolism (PROACT) trials, 11, 12 but is not currently available for clinical use in the US. Presently, t-PA is the only agent approved by the FDA speci fi cally for IV thrombolysis for ischaemic stroke. Third-generation agents include reteplase and tenecteplase and offer the theoretical advantages of longer half-lives and greater penetration into the thrombus matrix when compared to the s...